Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1964 2
1965 2
1966 1
1967 4
1968 1
1969 1
1970 4
1971 2
1972 3
1973 9
1974 5
1975 24
1976 29
1977 28
1978 31
1979 28
1980 55
1981 58
1982 60
1983 62
1984 90
1985 104
1986 85
1987 120
1988 128
1989 170
1990 209
1991 190
1992 217
1993 245
1994 261
1995 266
1996 299
1997 289
1998 291
1999 336
2000 326
2001 352
2002 356
2003 461
2004 440
2005 459
2006 538
2007 614
2008 611
2009 691
2010 768
2011 834
2012 866
2013 942
2014 1011
2015 1088
2016 1105
2017 1045
2018 1166
2019 1325
2020 1431
2021 1395
2022 1311
2023 1190
2024 408

Text availability

Article attribute

Article type

Publication date

Search Results

21,637 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Advanced Malignant Genitourinary System Neoplasm"
Page 1
Cancer statistics, 2022.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Siegel RL, et al. CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. CA Cancer J Clin. 2022. PMID: 35020204 Free article.
Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed a …
Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate ca …
Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH Jr, Safra T, Italiano A, Mileshkin L, Xu L, Jin F, Norwood K, Maio M. O'Malley DM, et al. J Clin Oncol. 2022 Mar 1;40(7):752-761. doi: 10.1200/JCO.21.01874. Epub 2022 Jan 6. J Clin Oncol. 2022. PMID: 34990208 Free PMC article. Clinical Trial.
METHODS: Eligible patients from cohorts D (endometrial cancer, regardless of MSI-H/dMMR status) and K (any MSI-H/dMMR solid tumor, except colorectal) with previously treated, advanced MSI-H/dMMR endometrial cancer received pembrolizumab 200 mg once every 3 weeks for 35 cyc …
METHODS: Eligible patients from cohorts D (endometrial cancer, regardless of MSI-H/dMMR status) and K (any MSI-H/dMMR solid tumor, except co …
Cervical cancer.
Moore DH. Moore DH. Obstet Gynecol. 2006 May;107(5):1152-61. doi: 10.1097/01.AOG.0000215986.48590.79. Obstet Gynecol. 2006. PMID: 16648423 Review.
Until recently, the greatest strides in reducing cervical cancer mortality have occurred with the advent and implementation of screening programs. Many important advances have also taken place in the diagnosis and treatment of cervical cancer. ...Management alternatives fo …
Until recently, the greatest strides in reducing cervical cancer mortality have occurred with the advent and implementation of screening pro …
Adaptive Immunity in Genitourinary Cancers.
Koti M, Bivalacqua T, Black PC, Cathomen T, Galsky MD, Gulley JL, Ingersoll MA, Kamat AM, Kassouf W, Siemens DR, Gao J. Koti M, et al. Eur Urol Oncol. 2023 Jun;6(3):263-272. doi: 10.1016/j.euo.2023.03.002. Epub 2023 Apr 15. Eur Urol Oncol. 2023. PMID: 37069029 Free article. Review.
OBJECTIVE: To review the literature and describe the key adaptive immune physiological events associated with cancer progression and therapeutic response in genitourinary (GU) cancers. EVIDENCE ACQUISITION: We performed a nonsystematic, collaborative narrative review to hi …
OBJECTIVE: To review the literature and describe the key adaptive immune physiological events associated with cancer progression and therape …
piRNAs and PIWI Proteins as Diagnostic and Prognostic Markers of Genitourinary Cancers.
Hanusek K, Poletajew S, Kryst P, Piekiełko-Witkowska A, Bogusławska J. Hanusek K, et al. Biomolecules. 2022 Jan 22;12(2):186. doi: 10.3390/biom12020186. Biomolecules. 2022. PMID: 35204687 Free PMC article. Review.
The mechanisms by which piRNAs regulate transposon and gene expression include DNA methylation, histone modifications, and mRNA degradation. Genitourinary cancers (GC) are a large group of neoplasms that differ by their incidence, clinical course, biology, an …
The mechanisms by which piRNAs regulate transposon and gene expression include DNA methylation, histone modifications, and mRNA degradation. …
Pediatric genitourinary tumors.
Merguerian PA. Merguerian PA. Curr Opin Oncol. 2003 May;15(3):222-6. doi: 10.1097/00001622-200305000-00008. Curr Opin Oncol. 2003. PMID: 12778016 Review.
Advances continue to be made in the evaluation and treatment of genitourinary tumors in children. Continued research on the cellular, molecular, and genetic process in tumorigenesis is rapidly evolving. We review the 2002 literature on pediatric genitourinary …
Advances continue to be made in the evaluation and treatment of genitourinary tumors in children. Continued research on the ce …
Pediatric genitourinary tumors.
Castellino SM, McLean TW. Castellino SM, et al. Curr Opin Oncol. 2007 May;19(3):248-53. doi: 10.1097/CCO.0b013e3280ad43ce. Curr Opin Oncol. 2007. PMID: 17414644 Review.
Recognition and treatment of anaplastic histology and bilateral Wilms' tumor remains a challenge. In rhabdomyosarcoma, genitourinary site and embryonal histology confer a relatively favorable prognosis. SUMMARY: Advances in molecular oncology, diagnostic imag …
Recognition and treatment of anaplastic histology and bilateral Wilms' tumor remains a challenge. In rhabdomyosarcoma, genitourinary …
Epidemiology of gynecologic cancers in China.
Jiang X, Tang H, Chen T. Jiang X, et al. J Gynecol Oncol. 2018 Jan;29(1):e7. doi: 10.3802/jgo.2018.29.e7. J Gynecol Oncol. 2018. PMID: 29185265 Free PMC article. Review.
Survival rates of gynecologic cancers are generally not satisfactory and decrease along with advancing stage, though national data on survival are still not available. ...
Survival rates of gynecologic cancers are generally not satisfactory and decrease along with advancing stage, though national data on …
Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis.
Guo M, Xu J, Du J. Guo M, et al. BMC Public Health. 2021 Jul 6;21(1):1329. doi: 10.1186/s12889-021-11401-8. BMC Public Health. 2021. PMID: 34229639 Free PMC article.
BACKGROUND: Worldwide, cervical cancer is the second-most-common malignancy of the female reproductive system. Due to its large population, China accounted for 11.9% of cervical cancer deaths, and 12.3% of global cervical cancer DALYs in 2017. ...Correspondingly, mortality …
BACKGROUND: Worldwide, cervical cancer is the second-most-common malignancy of the female reproductive system. Due to its large popul …
Practical Molecular Testing in a Clinical Genitourinary Service.
Magers MJ, Cheng L. Magers MJ, et al. Arch Pathol Lab Med. 2020 Mar;144(3):277-289. doi: 10.5858/arpa.2019-0134-RA. Epub 2019 Aug 2. Arch Pathol Lab Med. 2020. PMID: 31373513 Free article. Review.
.-: Molecular testing is increasingly playing a key role in the diagnosis, prognosis, and treatment of neoplasms of the genitourinary system. ...CONCLUSIONS.-: Understanding of the molecular oncology of genitourinary neoplasms is rapidly …
.-: Molecular testing is increasingly playing a key role in the diagnosis, prognosis, and treatment of neoplasms of the gen …
21,637 results
You have reached the last available page of results. Please see the User Guide for more information.